GERN vs. LXRX

In the year-to-date period, GERN achieves a 0.85% return, which is significantly lower than LXRX's 6.78% return. Over the past 10 years, GERN has outperformed LXRX with an annualized return of 1.36%, while LXRX has yielded a comparatively lower -18.94% annualized return.

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.

This table presents a comparison of risk-adjusted performance metrics for Geron Corporation (GERN) and Lexicon Pharmaceuticals, Inc. (LXRX). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.

The current GERN Sharpe Ratio is 0.70, which is higher than the LXRX Sharpe Ratio of -0.47. The chart below compares the historical Sharpe Ratios of GERN and LXRX, offering insights into how both investments have performed under varying market conditions. These values are calculated using daily returns over the previous 12 months.

Neither GERN nor LXRX has paid dividends to shareholders.

The maximum GERN drawdown since its inception was -98.65%, roughly equal to the maximum LXRX drawdown of -99.80%. Use the drawdown chart below to compare losses from any high point for GERN and LXRX. For additional features, visit the drawdowns tool.

The current volatility for Geron Corporation (GERN) is 10.75%, while Lexicon Pharmaceuticals, Inc. (LXRX) has a volatility of 34.30%. This indicates that GERN experiences smaller price fluctuations and is considered to be less risky than LXRX based on this measure. The chart below showcases a comparison of their rolling one-month volatility.

This section allows you to compare key financial metrics between Geron Corporation and Lexicon Pharmaceuticals, Inc.. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.